Table II.
Summary of Efficacy Results at Week 8
| Study 1 | Study 2 | Pooled Data | ||||
|---|---|---|---|---|---|---|
| Candesartan | Candesartan | Candesartan | ||||
| Characteristic | Lisinopril (n=267) | + Lisinopril (n=270) | Lisinopril (n=277) | + Lisinopril (n=278) | Lisinopril (n=544) | + Lisinopril (n=548) |
| Least squares mean change in SBP/DBP (mm Hg) | ‐6.24/‐5.90 | ‐11.58†/‐8.29† | ‐8.72/‐6.24 | ‐9.48/‐7.44 | ‐7.24/‐6.49 | ‐10.37†/‐8.21† |
| Responder (n [%])* | 134 (50.2) | 159 (58.9)ɛ | 158 (57.0) | 169 (60.8) | 292 (53.7) | 328 (59.9) |
| Controlled (n [%]) | ||||||
| DBP <90 mm Hg | 126 (47.2) | 144 (53.3) | 143 (51.6) | 158 (56.8) | 269 (49.4) | 302 (55.1) |
| SBP <140 mm Hg | 127 (47.6) | 148 (54.8) | 146 (52.7) | 154 (55.4) | 273 (50.2) | 302 (55.1) |
| SBP/DBP <140/<90 mm Hg | 90 (33.7) | 114 (42.2)ɛ | 111 (40.1) | 120 (43.2) | 201 (36.9) | 234 (42.7) |
| All blood pressure measurements were obtained at trough in the sitting position. *DBP <90 mm Hg or reduced by ≥10 mm Hg; † p<0.01 vs. lisinopril monotherapy; ɛ p=;0.05 vs. lisinopril monotherapy | ||||||